Silexion Sets Oct 19 Vote on 500M Share Increase and 1-for-15 to 1-for-25 Reverse Split to Save Nasdaq Listing
SLXN is trading near its 52-week low of $0.236 (13% above the low) on light trading volume (0.1× avg).
Summary
Silexion's definitive proxy sets an October 19 vote on a 500M share authorization increase and a 1-for-15 to 1-for-25 reverse split, its second attempt after shareholders rejected a smaller proposal in September. The company has exhausted its authorized shares and needs approval to cover outstanding warrants and maintain Nasdaq listing.
Key Events · Corporate Governance and Compliance · SLXN
-
Second Attempt at Share Authorization Increase
Seeks approval to increase authorized shares by 500 million, from 15.9 million to 515.9 million — a 3,145% increase. Shareholders rejected a smaller 175 million share increase on September 25, 2026.
-
Reverse Split to Regain Nasdaq Compliance
Proposes a reverse split of between 1-for-15 and 1-for-25 to lift the share price above the $1.00 Nasdaq minimum bid requirement. The stock has traded below $1.00 for 30 consecutive days, triggering a delisting notice on September 25, 2026.
-
Zero Authorized Shares Remaining
As of September 30, 2026, all 15.9 million authorized shares are either issued (14.47M) or reserved for warrants and equity plans, leaving zero available for new issuances.
-
Warrant Exercise Blocked Without Approval
6,659,041 Series F, Series G, and placement agent warrants from the September 2026 induced warrant exercise cannot be exercised until shareholders approve this authorization increase.
Analysis · SLXN · Life Sciences
Silexion is asking shareholders to approve a 500 million share authorization increase and a reverse split of between 1-for-15 and 1-for-25 at an October 19 meeting. The company has zero authorized unissued shares remaining and needs the increase to cover 6.66 million warrants from its September induced warrant exercise and to maintain the $2.5 million Nasdaq equity minimum. Shareholders rejected a smaller 175 million share increase and a 1-for-15 reverse split on September 25, so this is a second, larger attempt to avoid delisting. The reverse split would mechanically lift the stock price above $1.00, but the authorization increase would enable massive future dilution — up to 3,145% more authorized shares than currently exist.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.